Home
Live Updates
Recombinant Zoster Vaccine Demonstrates High Protection Against Shingles in Adult Patients : vimarsana.com
Recombinant Zoster Vaccine Demonstrates High Protection Against Shingles in Adult Patients
The recombinant zoster vaccine demonstrated a 79.7% efficacy in patients aged 50 years and older cumulatively within the 6- to 11-year period after vaccination.
Related Keywords
Spain ,
Barcelona ,
Comunidad Autonoma De Cataluna ,
Phil Dormitzer ,
Glaxosmithkline ,
Biomedical Research Of The Valencian Community ,
Foundation For The Promotion Of Health ,
European Society Of Clinical Microbiology ,
Long Term Follow Up Study ,
Two Studies ,
Immunogenicity Persistence ,
Herpes Zoster Subunit ,
Two Subgroups ,
Biomedical Research ,
Valencian Community ,
European Society ,
Clinical Microbiology ,
Infectious Diseases Global ,
vimarsana.com © 2020. All Rights Reserved.